A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Mightier Raises $17 Million to Support Growing Number of Kids Struggling with Emotional Health due to Pandemic

Series B Round, led by DigiTx Partners with Sony Innovation Fund and PBJ Capital, will help program expand into new markets, reach more children in need

Mightier an accessible and clinically proven video game system that helps children learn coping skills to improve their emotional health, today announced a $17 million Series B funding round. The round was led by DigiTx Partners with participation from the Sony Innovation Fund and Boston-based PBJ Capital. To date, Mightier has raised $29 million.

Since its launch in 2018, Mightier has helped over 50,000 families with children who struggle with anxiety, tantrums and anger, as well as clinical diagnoses such as attention deficit hyperactivity disorder (ADHD), oppositional defiant disorder (ODD) and autism spectrum disorder (ASD). Developed by clinicians at Boston Children’s Hospital and Harvard Medical School, Mightier pairs video games with clinically validated strategies to help children learn the coping skills they need to regulate their emotions by playing and interacting with biofeedback.

Mightier is a clinically validated, at-home solution families can access immediately that has been shown to help over 80% of children within the first three months. This latest funding will help Mightier expand its team and scale its proven technology to reach more children who struggle with their emotions. The funds will also help Mightier expand its reach into the healthcare industry through a strategic partnership the company entered with Magellan Health earlier this year.

Children’s behavioral and emotional health struggles have exacerbated due to the pandemic, and there is a shortage of clinicians to meet the rising need. Just last week, the United States Surgeon General Dr. Vivek H. Murthy issued a 53-page public report on children’s mental health noting that the pandemic has intensified mental health struggles that were already widespread during the spring of 2020. This report comes on the heels of an urgent warning from leaders of the American Academy of Pediatrics, the Children’s Hospital Association, and the American Academy of Child and Adolescent Psychiatry declaring the mental health crisis among children a national emergency.

“The mental and emotional health struggles of children in the US have been a longstanding issue that has worsened during the past two years and the current support systems available have not met the rising demand,” said David Kim, MD, Managing Director of DigiTx Partners. “We are drawn to Mightier and its leadership team because of its proven ability to help families experiencing those struggles with an innovative, easy-to-use solution that provides immediate impact. We are excited to support a company positioned to play a meaningful role in the future wellbeing of our children.”

“Families need more options to support the emotional needs of their kids now more than ever. Mightier is the only evidence-based solution that can serve families anywhere in the country in the comfort of their homes with fun, engaging content and a community of kids, caregivers and experts who understand them,” said Craig Lund, co-founder and chief executive officer at Mightier. “Our new investors bring valuable health care and gaming expertise to the company to help us scale our program to reach even more families and kids in need of support.”

Mightier’s technology has been tested in several clinical trials and has consistently shown to improve behavior. After 12 weeks of Mightier’s program, families have reported positive changes in three key areas — child outbursts, child oppositional behavior, and parental stress. In its partnership with Magellan Healthcare, Mightier began offering its video game program to health plans and employers. In the last year, Mightier has also collaborated with the managed health care company on several studies and pilot programs to research the impact of video games on improving children’s mental health and, more specifically, the success of using Mightier to support children with autism. The later study, completed in May of this year, found Mightier led to a 45% improvement in symptoms for children on the autism spectrum.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

With this new investment partnership, E Tech Group expects to accelerate organic growth and acquisition to become a top system integrator in North America.
The investment will allow ROM InWest to further distribute its fall detection product globally.
Nawal Ouzren, Sensorion’s Chief Executive Officer, said: “We are thrilled to announce another successful capital raise, securing an additional EUR 15 million to accommodate interest expressed by certain existing investors. This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months. With this new financing, we are well-positioned to accelerate our gene therapy programs, including the progression of SENS-501 through its Phase 1/2 clinical study, Audiogene, and the advancement of our second program, GJB2-GT, towards Clinical Trial Applications submission in H1 2025. The capital increase enables the Company to finance its activities until the end of 2025. We remain deeply thankful for the ongoing support of our shareholders and partners as we strive to make a meaningful difference in the lives of those affected by hearing loss disorders.”
Strategic Investor, Osang Healthcare will partner with Kryptos Biotechnologies for the manufacturing and distribution of the product along with financing.
Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC). Obsidian Therapeutics is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.

By using this website you agree to accept Medical Device News Magazine Privacy Policy